Neuromyelitis Optica Spectrum Disorder Market Report 2025

The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth observed during the historical period can be attributed to factors such as the increasing prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD), greater awareness and early diagnosis, expanding therapeutic options and FDA approvals, growing research and development activities, and an increase in clinical trials for new therapies.

The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to $3.52 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period is expected to be driven by rising awareness and early diagnosis, higher healthcare spending, increased investments in research and development, the growing prevalence of autoimmune diseases, more clinical trials for NMOSD therapies, and a rising demand for personalized medicine. Key trends for the forecast period include advancements in precision medicine, increased collaboration and partnerships, technological innovations, the integration of AI and big data in research, and a shift towards home-based treatments.

The rising prevalence of multiple sclerosis (MS) is expected to drive the growth of the neuromyelitis optica spectrum disorder (NMOSD) market. Multiple sclerosis is a chronic autoimmune disease that affects the central nervous system, causing inflammation, nerve damage, and neurological symptoms. The increasing prevalence of MS is attributed to improved diagnostic techniques, environmental factors, and genetic predisposition. Advancements in medical imaging, such as MRI, have enabled earlier and more accurate diagnoses, contributing to a rise in detected cases. As the number of MS diagnoses increases, there is greater awareness of neurological autoimmune diseases, which has led to improved diagnostic methods and a better understanding of conditions such as NMOSD. For example, in May 2024, the Multiple Sclerosis Trust reported that the UK sees around 7,100 new MS cases annually, with approximately 135 new diagnoses each week. Therefore, the growing prevalence of MS is fueling the growth of the NMOSD market.

Companies in the NMOSD market are focusing on developing innovative treatments, such as long-acting complement inhibitors, to enhance the effectiveness of therapies and improve patient outcomes. Long-acting complement inhibitors are designed to suppress the complement system for extended periods, preventing inflammation and nerve damage in NMOSD. These treatments help reduce relapses and contribute to long-term disease management. For instance, in March 2024, Alexion Pharmaceuticals, a U.S.-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical firm, received approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive NMOSD. ULTOMIRIS is the first and only long-acting C5 complement inhibitor approved for NMOSD treatment. The approval was based on the Phase III CHAMPION-NMOSD trial, which showed a 98.6% reduction in relapse risk over 73 weeks compared to a placebo, with no new safety concerns identified during the trial.

In October 2023, Amgen, a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition allows Amgen to expand its portfolio in rare and autoimmune diseases, strengthening its position in the NMOSD market with treatments such as UPLIZNA (ibalizumab-con) for adult patients who are anti-aquaporin-4 (AQP4) antibody-positive. Horizon Therapeutics, based in Ireland, specializes in treatments for NMOSD.

Major players in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics.

North America was the largest region in the neuromyelitis optica spectrum disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuromyelitis optica spectrum disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neuromyelitis optica spectrum disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that primarily affects the central nervous system, focusing on the spinal cord and optic nerves. The condition is characterized by severe inflammation and demyelination (damage to the protective sheath of nerve fibers) in these areas, leading to symptoms such as vision loss, paralysis, and sensory dysfunction.

The primary types of neuromyelitis optica spectrum disorder include NMOSD with aquaporin-4 antibodies and NMOSD without aquaporin-4 antibodies. NMOSD with aquaporin-4 antibodies occurs when the immune system mistakenly attacks nerve fibers, causing inflammation, vision impairment, and paralysis. Diagnosis is made through various methods, including imaging tests, magnetic resonance imaging (MRI), blood tests, and more. Treatment options include C5 protein inhibitors, monoclonal antibodies, plasma exchange therapy, corticosteroids, immunoglobulin therapy, medications, and others. These treatments are distributed through different channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a range of end-users, including hospitals, specialty clinics, and home care settings.

The neuromyelitis optica spectrum disorder market research report is one of a series of new reports that provides neuromyelitis optica spectrum disorder market statistics, including the neuromyelitis optica spectrum disorder industry global market size, regional shares, competitors with the neuromyelitis optica spectrum disorder market share, detailed neuromyelitis optica spectrum disorder market segments, market trends, and opportunities, and any further data you may need to thrive in the neuromyelitis optica spectrum disorder industry. This neuromyelitis optica spectrum disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neuromyelitis optica spectrum disorder market consists of revenues earned by entities by providing services such as rehabilitation services, patient assistance programs, and intravenous immunoglobulin (IVIG) therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuromyelitis optica spectrum disorder market includes sales of immunosuppressants, corticosteroids, and symptomatic treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.